Search:    About Us Product Lines Medical professionals Patients Investors What's New Contact Us   Our Vision Executive Management Board of Directors   About Us >> Board of Directors Board of Directors Mr. Abraham Nahmias Chairman of the Board Mr. Abraham Nahmias has more than fifteen years of experience as a director in a several public companies. In addition to that he is a senior partner in an accounting firm and serves as an internal auditor in a few companies. Mr. Nahmias is a Certified Public Accountant and holds a Bachelor's degree in Accounting and Economics from Tel Aviv University.   Dr. David M. Milch, Founder and Vice Chairman Dr. Milch is a 1980 graduate of Harvard Medical School, having completed his undergraduate studies in biology at Stanford University in 1976. Upon finishing his clinical and research responsibilities in 1984, Dr. Milch moved to New York City to pursue a business career. Between 1980 and 1989 Dr. Milch has been a principal of Bermil Industries, a closely held corporation controlled by the Milch Family, involved with capital equipment manufacture and distribution, financing, real estate development, and other entrepreneurial activities. After a portion of Bermil was sold to a public company in 1989, Dr. Milch turned a significant portion of his time and attention to venture investments in technology and the life sciences. Dr. Milch and his associates have invested in or advised on a wide variety opportunities including The American Blood Institute (private sale), Intelligent Medical Imaging (IPO), Biofield (IPO), Nitinol (IPO), Datatec Systems (reverse merger), Warp Technologies (reverse merger), MiniMed (acquired by Medtronic), Advanced Bionics (acquired by Boston Scientific), Theravance (IPO), and others. Recently his activity has focused on medical device companies from Israel.   Dr. Jacob Dagan, Director Dr. Dagan has more than twenty five years of experience in management, operations, sales, finance, organizational planning and business development in the medical services and device sectors for public and private companies in the US and Israel. Since the beginning of 2011, responsible for Life Science investments at Migdal Capital Markets- Underwriting and Business Initiative Company.  Since 2005 partner in ProMed Capital, LLC. Held the position of Director of BioMedical Engineering of the Sheeba Medical Center and Associate Professor of Bio-Medical Engineering at Tel Aviv University. For seven years held senior management positions with Sharplan Lasers,. Dr. Dagan has been Involved in fund raising and strategy consulting to Bio-Medical, Bio-Technology companies and on the Board or in operating responsibilities of several start-ups, including Biofield Corp. (CEO), Heart-Guard, Inc. (CEO) and more. Dr. Dagan received his Doctorate from Columbia University, a MSc in Nuclear Sciences from the Technion and a B.Sc. in Mechanical and Nuclear Engineering from the Technion, Israel Inst. of Technology.   Dr. Ehud Geller, Director  Dr. Ehud Geller co-founded Medica Venture Partners in 1995. He brings over 30 years of senior executive operational experience in healthcare companies, both in the U.S. and Israel. From 1985 to 1990, Dr. Geller served as the President and CEO of Interpharm Laboratories, Ltd. and was instrumental in bringing this publicly traded company to a market capitalization of over $380 million, with its leading product, REBIF, a product whose revenues ultimately reached $2 billion. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva and Executive VP of the Teva Group, the world’s largest generic pharmaceutical company. At Teva, he led the acquisition of Ikapharm Ltd. and formulated the company’s successful strategy for entry into the U.S. market. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange (TASE).

 Dr. Geller began his industry career at Wyeth Laboratories in the U.S., where he spent seven years with responsibilities ranging from pharmaceutical research through pilot plant operations and corporate new product introduction management. Dr. Geller has a B.Sc. in chemical engineering, an MBA from Columbia University/Drexel Institute and a Ph.D. in pharmaceutical/chemical engineering from Drexel Institute, Philadelphia.